Comparing SG&A Expenses: AstraZeneca PLC vs Dr. Reddy's Laboratories Limited Trends and Insights

SG&A Expenses: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. AstraZeneca PLC and Dr. Reddy's Laboratories Limited, two titans in the field, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, AstraZeneca's SG&A expenses have seen a steady increase, peaking in 2022 with a 95% rise from its 2016 low. Meanwhile, Dr. Reddy's Laboratories has consistently outpaced AstraZeneca, with expenses more than doubling by 2023, reaching a staggering 105% increase from 2014. This divergence highlights the strategic differences in their operational expenditures. Notably, 2024 data for AstraZeneca is missing, leaving room for speculation on future trends. As these companies navigate the complexities of global healthcare, their financial strategies offer a window into their competitive positioning.